Strange love-in here. Lots of preliminary results about lots of different biomarkers, that in themselves, have not been studied or shown to be of any clinical benefit when targeted.. and then ANP are saying that their drug may have effect against a couple of them? And it's not even known if targeting one or two of these biomarkers would have any therapeutic benefit? give me a spell.
Ann: Long Covid-19 Collaboration Outcomes Presentation, page-40
-
- There are more pages in this discussion • 189 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
-0.003(3.37%) |
Mkt cap ! $77.53M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 8.9¢ | 8.5¢ | $584.3K | 6.750M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 379793 | 8.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |